Charles River Laboratories International, Inc. $CRL Stock: Yousif Capital Management LLC Boosts Holdings

Yousif Capital Management LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 721.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 43,367 shares of the medical research company’s stock after purchasing an additional 38,090 shares during the quarter. Yousif Capital Management LLC’s holdings in Charles River Laboratories International were worth $12,794,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Compass Wealth Management LLC purchased a new stake in Charles River Laboratories International in the third quarter valued at approximately $69,000. Cardinal Capital Management raised its position in Charles River Laboratories International by 4.9% during the 3rd quarter. Cardinal Capital Management now owns 11,756 shares of the medical research company’s stock worth $3,468,000 after buying an additional 550 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in Charles River Laboratories International by 197.3% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 12,773 shares of the medical research company’s stock worth $3,768,000 after buying an additional 8,476 shares during the last quarter. Physician Wealth Advisors Inc. lifted its stake in Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 55 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Charles River Laboratories International by 150.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 30,746 shares of the medical research company’s stock valued at $9,070,000 after acquiring an additional 18,482 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon Parisotto sold 5,046 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael Knell sold 6,645 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. This trade represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 94,127 shares of company stock valued at $26,776,516 in the last three months. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded up $5.42 during trading on Friday, hitting $345.08. 822,279 shares of the stock traded hands, compared to its average volume of 1,091,356. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The company has a fifty day moving average price of $294.35 and a two-hundred day moving average price of $233.22. Charles River Laboratories International, Inc. has a 52-week low of $146.20 and a 52-week high of $351.21. The company has a market cap of $16.47 billion, a price-to-earnings ratio of -71.15, a P/E/G ratio of 3.17 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Analyst Ratings Changes

CRL has been the topic of a number of research reports. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Argus set a $330.00 target price on shares of Charles River Laboratories International in a research report on Thursday, September 17th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price target for the company from $180.00 to $310.00 in a report on Thursday, August 6th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Royal Bank Of Canada increased their price target on Charles River Laboratories International from $282.00 to $322.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus price target of $302.33.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.